Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events maximum · patients with acute coronary syndrome
Drug‐eluting stents may leads to lower serious adverse events at maximum compared with bare‐metal stents (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
SAEs · participants with obesity
1 finding from 1 review
SAEs · participants with obesity
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Intervention not reported
One or more serious adverse events · cognitively healthy people in midlife
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Intervention not reported
People with serious adverse events · people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review